Over the past several decades, Michael Kinch of Washington University in St. Louis says, the pharmaceutical industry has managed to dismantle itself. In a provocative series of articles and interviews, Kinch, the director of the Center for Research Innovation in Businessat the university, has been describing the history of this dismantling and its implications for the future of medicine.
Andrew and Barbara Taylor and the Crawford Taylor Foundation, the charity of the entire Jack C. Taylor family, have committed $20 million to the Department of Psychiatry at the School of Medicine to advance the science underlying the diagnosis and treatment of psychiatric illnesses. The gift creates the new Taylor Family Institute for Innovative Psychiatric Research.
The first trial of a new model for testing Alzheimer’s treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.